Skip to main content

People in the News: Nov 11, 2010


Alnylam Pharmaceuticals said that it has expanded its management team to include two new vice presidents and a CSO.

Kenneth Koblan, who has been named CSO, previously held various positions within Merck Research Laboratories, most recently vice president and site head of Rahway Basic Research. He holds a PhD in biochemistry from Johns Hopkins University.

Alnylam's previous CSO, John Schmidt, left the company in August of 2009.

The company also said that it has appointed Steven Bossone as its vice president of intellectual property and Garvin Warner as its vice president of preclinical development.

Bossone previously served as senior patent attorney at Shire, and had worked as a scientist in the oncology group of Millennium Pharmaceuticals. Warner previously served as assistant vice president and therapeutic area head in drug safety and metabolism at Genetics Institute/Wyeth.

The Scan

And For Adolescents

US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.